Premium
Critical questions in ovarian cancer research and treatment: Report of an American Association for Cancer Research Special Conference
Author(s) -
Bast Robert C.,
Matulonis Ursula A.,
Sood Anil K.,
Ahmed Ahmed A.,
Amobi Adaobi E.,
Balkwill Frances R.,
WielgosBonvallet Monicka,
Bowtell David D. L.,
Brenton James D.,
Brugge Joan S.,
Coleman Robert L.,
Draetta Giulio F.,
Doberstein Kai,
Drapkin Ronny I.,
Eckert Mark A.,
Edwards Robert P.,
Elias Kevin M.,
Ennis Darren,
Futreal Andrew,
Gershenson David M.,
Greenberg Roger A.,
Huntsman David G.,
Ji Jennifer Xiao Ye,
Kohn Elise C.,
Iavarone Claudia,
Lengyel Ernst R.,
Levine Douglas A.,
Lord Christopher J.,
Lu Zhen,
Mills Gordon B.,
Modugno Francesmary,
Nelson Brad H.,
Odunsi Kunle,
Pilsworth Jessica A.,
Rottapel Robert K.,
Powell Daniel J.,
Shen Li,
Shih IeMing,
Spriggs David R.,
Walton Josephine,
Zhang Kaiyang,
Zhang Rugang,
Zou Lee
Publication year - 2019
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/cncr.32004
Subject(s) - medicine , ovarian cancer , disease , cancer , chemotherapy , immunotherapy , oncology , translational research , intensive care medicine , pathology
Substantial progress has been made in understanding ovarian cancer at the molecular and cellular level. Significant improvement in 5‐year survival has been achieved through cytoreductive surgery, combination platinum‐based chemotherapy, and more effective treatment of recurrent cancer, and there are now more than 280,000 ovarian cancer survivors in the United States. Despite these advances, long‐term survival in late‐stage disease has improved little over the last 4 decades. Poor outcomes relate, in part, to late stage at initial diagnosis, intrinsic drug resistance, and the persistence of dormant drug‐resistant cancer cells after primary surgery and chemotherapy. Our ability to accelerate progress in the clinic will depend on the ability to answer several critical questions regarding this disease. To assess current answers, an American Association for Cancer Research Special Conference on “Critical Questions in Ovarian Cancer Research and Treatment” was held in Pittsburgh, Pennsylvania, on October 1‐3, 2017. Although clinical, translational, and basic investigators conducted much of the discussion, advocates participated in the meeting, and many presentations were directly relevant to patient care, including treatment with poly adenosine diphosphate ribose polymerase (PARP) inhibitors, attempts to improve immunotherapy by overcoming the immune suppressive effects of the microenvironment, and a better understanding of the heterogeneity of the disease.